Genome-wide expression profiling revealed overexpression of the gene encoding frizzled homologue 10 (FZD10), a cell-surface receptor for molecules in the Wnt pathway, as a potential contributor to synovial sarcomas (SS). Northern blotting and immunohistochemical staining confirmed that expression levels of FZD10 were very high in nearly all SS tumors and cell lines examined but absent in most normal organs or in some cancers arising in other tissues. Treatment of human SS cells with small-interfering RNA (siRNA) to FZD10 decreased the amount of its product and suppressed growth of SS cells. Moreover, a polyclonal antibody specifically recognizing the extracellular domain (ECD) of FZD10 was markedly effective in mediating ADCC against FZD10-overexpressing synovial sarcoma cells in vitro. Injection of the antibody into SS xenografts in nude mice attenuated tumor growth, and TUNEL assays revealed clusters of apoptotic cells in antibodytreated xenografts. Taken together, these findings suggest that a humanized antibody against FZD10 might be a promising treatment for patients with tumors that overexpress FZD10; minimal or no adverse reactions would be expected because FZD10 protein is not abundant in vital organs.
Introduction
Humanized monoclonal antibodies, such as trastuzumab against ErbB2 and rituximab against CD20, have contributed to remarkable improvement of clinical outcomes in some cases of breast cancer and malignant lymphoma (Fendly et al., 1990; Maloney et al., 1997) . Humanized antibodies are thought to exert antitumor effects by inhibiting transduction of growth signals either by blocking cell-surface receptors or downregulating target molecules, and/or by contributing to antibody-dependent cell-mediated cytotoxicity (ADCC). Those promising observations imply that a genome-wide search for cancer-specific cell-surface molecules should be an effective approach to development of new treatments for various types of cancer.
Among malignant tumors occurring in mesenchymal tissues, osteosarcomas, Ewing's sarcomas and rhabdomyosarcomas are generally sensitive to chemotherapy. However, other sarcomas, especially spindle-cell sarcomas in adults such as synovial sarcomas (SS), are chemo and radiation resistant and show poor prognosis (Sarcoma Meta-analysis Collaboration, 1997; Wunder et al., 1998; Crist et al., 2001; Ferguson and Goorin, 2001) . Therefore, novel treatment modalities including antibody-based therapy need to be developed in the interest of further improvement.
If one is to avoid severe adverse reactions, a critical issue for development of any antibody-based therapy is to identify cell-surface molecules that are overexpressed in the majority of the target tumors but are absent or barely detectable in normal tissues. Based upon a genome-wide analysis of gene-expression profiles of soft-tissue sarcomas, we identified 26 genes that were commonly upregulated in SS (Nagayama et al., 2002) . From among them we selected a likely candidate, Frizzled homologue 10 (FZD10), whose product belongs to the Frizzled family of seven-pass transmembrane receptors for molecules in the Wnt signaling pathway. Our criteria for selection were: (i) very low or absent expression in vital organs including the brain, heart, lung, liver, kidney and bone marrow; and (ii) location of the predicted product in the plasma membrane. Upregulation of FZD10 has been reported in primary colorectal cancers (Terasaki et al., 2002) and primary gastric cancers (Kirikoshi et al., 2001) as well as SS, but the precise biological behavior of FZD10 in regard to tumorigenesis remains obscure.
In this study, we generated a specific polyclonal antibody that recognized the N-terminal extracellular domain (ECD), of FZD10 as a step toward development of antibody-based therapy for SS. The results of our experiments, in vitro and in vivo, have led us to believe that a humanized antibody against FZD10-ECD would have therapeutic potential for treatment of SS and other tumors that overexpress FZD10. We also demonstrated that suppression of FZD10 can inhibit growth of SS cells. These observations suggested that overexpression of FZD10 might be a key factor for tumorigenesis of synovial sarcoma.
Results

Expression of FZD10 mRNA in normal adult tissues and tumor samples
Northern blot analysis revealed that FZD10 was expressed to any significant degree only in placenta among the normal adult human tissues examined (Figure 1a ), in accordance with a previous report (Koike et al., 1999) . However, this gene was expressed in SS surgical specimens SS487 and SS582, as well as in SS cell lines HS-SY-2 and YaFuSS, at higher levels than in placenta. We found no detectable signals in coloncancer cell lines SW480, HT29 or LoVo (Figure 1b) .
Recognition of FZD10-ECD by a specific polyclonal antibody
Using an affinity-purified antibody (TT641 pAb) that recognized FZD10-ECD, we observed a single band compatible with the expected molecular size of FZD10 protein in HS-SY-2, YaFuSS and HeLa cells where high levels of FZD10 transcript had been detected. This band was absent or hardly detectable in several colon-cancer cell lines (Figure 1c ). Since other proteins in the frizzled family are similar in size, we examined whether the 68-kD band recognized by TT641 pAb was specific to FZD10. When the levels of transcription of ten FZD genes were examined by semiquantitative RT-PCR (Figure 1d ), the pattern of FZD10 was quite similar to that detected by Western blotting with TT641 pAb, especially in regard to the HeLa and LoVo cell lines.
This finding supported a conclusion that TT641 pAb recognized epitope(s) of FZD10 but not other members of the FZD family.
To examine the subcellular localization of FZD10 protein, we established lines of COS7-FZD10 cells (S5, S9, S10, S3 and S11) that stably overexpressed FZD10 (Figure 1e ). When COS7-FZD10 cells were counterstained with Texas Red-conjugated anti-myc antibody, the red signal coincided with the green one of TT641 pAb (Figure 1f ), confirming specific binding of TT641 pAb to FZD10. Furthermore, the appearance of endogenous FZD10 in HS-SY-2 and YaFuSS cells corresponded to the expression pattern in stable transfectants (Figure 1g ). It is not clear why FZD10 appears in a dotted pattern in the cytoplasm, but we presume that mature cell-surface antigen would be present in relatively low concentrations, while abundant unprocessed proteins in the cytoplasm could be detectable by immunocytochemistry.
To clarify the question of subcellular localization, we performed flow cytometry using SS cell lines YaFuSS, HS-SY-2 and SYO-1 that were specifically labeled with TT641 pAb ( Figure 1h) ; no fluorescent signals were detected in HT29 or LoVo cell lines. These observations correlated with the expression levels of FZD10 observed on Northern blots (Figure 1b) . Taken together, the findings indicate that the TT641 pAb specifically recognizes the ECD of FZD10 under either native or denaturing conditions.
To further characterize the specificity of TT641 pAb, we performed epitope mapping using the SPOTs system (see Materials and methods). TT641 pAb recognized six different epitopes of FZD10-ECD in different degrees (Figure 2 ). The antibody showed the strongest reactivity to the epitope representing residues 214-226, a sequence likely to be critical for binding of TT641 pAb to FZD10-ECD.
FZD10 protein in normal adult human tissues and primary SS specimens
We designed immunohistochemical experiments to investigate whether TT641 pAb could specifically recognize FZD10 in normal adult human tissues and surgical SS specimens. Strong staining for FZD10 was observed in placenta ( Figure 3a ) but, as expected from Northern analysis, none was detected in normal brain, heart, lung or liver tissues (Figure 3b -e). In the normal kidney, however, positive staining was observed in the proximal and distal tubules (Figure 3f ). In the normal stomach ( Figure 3g and h), strong immunoreactivity was observed in the upper portion of gastric glands, but the intensity was much weaker in cells located at the bottom of the glands. Similarly, in the normal colon ( Figure 3i ) epithelial cells showed strong immunoreactivity of FZD10 only at the surface of the villi. In contrast, cytoplasmic staining especially strong in epithelial tumor cells of a biphasic SS specimen, while spindle cells showed only faint immunoreactivity ( protein appeared to be absent or low in normal vital organs compared to its highly increased expression in SS tissues. Colon-cancer cells from a primary lesion ( Figure 3l ) and liver lesions metastasized from the colon (Figure 3m and n) were also immunostained with TT641 pAb, but no detectable signal was observed in the stromal tissues of the colon or liver tissues surrounding the metastatic lesions.
Ability of TT641 pAb to mediate ADCC against FZD10-expressing SS cells
To examine whether TT641 pAb would induce antigendependent cell-mediated cytotoxicity (ADCC) against SS cells, we measured release of lactate dehydrogenase (LDH) from lysed SS cells. When target and effector cells were coincubated with 0.7 mg of TT641 pAb per well at an E : T ratio of 25 : 1, no cytotoxic effects occurred in the target cells (SYO-1) with TT641 pAb alone (T þ Ab), and we saw no evidence of cytotoxic interaction between TT641 pAb and human effector cells (E þ Ab) or between the target cells and human effector cells (T þ E) ( Figure 4a ). In contrast, cytotoxic effects were evident when the target cells were incubated with both the antibody and human effector cells
Even when the target cells were incubated with different concentrations of TT641 pAb in different E : T ratios, cytotoxicity was induced only when both the antibody and human effector cells were added at the same time. Addition of 1 mg of TT641 pAb per well induced about 100% of the cell-mediated cytotoxicity against FZD10-overexpressing cells at an E : T ratio of 25 : 1 (Figure 4b ). This cytotoxic effect was in positive correlation with the E : T ratios and the amount of antibody present. No significant ADCC was induced by a control antibody against the target cells. These results suggested that TT641 pAb might inhibit growth of FZD10-overexpressing tumors through the ADCC mechanism.
Inhibition of growth of SS xenografts by TT641 pAb
The growth of SS xenografts in nude mice was attenuated by treatment with TT641 pAb, as compared to treatment with nonimmunized rabbit IgG ( Figure 5 ). At day 6 after initiation of antibody treatment, SS xenografts in mice treated with TT641 pAb were significantly smaller than negative
We performed TUNEL analyses to clarify the mechanism involved. Tumor specimens treated with TT641 pAb showed clusters of apoptotic cells (Figure 6f and l), which were negative for cell-proliferation marker Ki-67 ( Figure 6e and k) ; no such clusters were observed in tumor specimens serving as negative controls ( Figure  6c and i). Since apoptotic cells in the tumors were surrounded by many viable cells (i.e., cells positive for Ki-67 staining; Figure 6e and k), the growth-inhibitory effect of TT641 pAb on SS xenografts appeared to be insufficient to cause drastic regression of the tumors.
Effect of FZD10-small-interfering RNAs (siRNAs) on growth of synovial sarcoma cell lines
To investigate the biological functions of FZD10, we constructed siRNA expression vectors specific to FZD10 under the control of the U6 promoter (psiU6BX-siFZD10, nonsilencing 1) (Table 1) , and transfected them into SYO-1 and HS-SY-2 cells, both of which express high levels of FZD10. Among the siRNA constructs tested, siFZD10 effectively reduced expression of FZD10 mRNA and protein compared with control siRNA (siEGFP). MTT and colony formation assays revealed that the number of viable cells was reduced in both cell lines in comparison with controls (Figure 7a and b) . These siRNAs did not affect expression of FZD9, which has the highest similarity to FZD10 in the Frizzled family. In addition, the effective siRNAs did not affect growth of A549 cells, which do not express FZD10 (data not shown), an indication that these siRNAs had no 'off-target effect'.
Oligomerization of FZD10
When exogenous HA-FLAG-FZD10 protein was immunoprecipitated with an a-HA antibody, a Western blot analysis using an a-HA antibody revealed exogenous FZD10 protein in the form of several bands that corresponded respectively to one, two or multiples of the predicted molecular mass. That observation suggested that FZD10 might form oligomers; (Kaykas et al., 2004) recently showed that Frizzled-family proteins can do that.
To investigate that hypothesis, we designed two kinds of tagged-FZD10 constructs (Figure 8a ) to examine homo-oligomerization. HA-FLAG-FZD10 and FZD10-myc-His were cotransfected into COS-7 cells and co-immunoprecipitated using a-HA antibody. Immunoprecipitated HA-FLAG-FZD10 yielded multiple bands as well (Figure 8b ). However, since co-immunoprecipi- FZD10; novel molecuar target for synovial sarcoma therapy S Nagayama et al tation of homo-oligomer was not observed when lysates from cells transfected with HA-FLAG-FZD10 or FZD10-myc were mixed before immunoprecipitation (data not shown), we concluded that FZD10 is able to constitute a homo-oligomer complex only in living cells.
Discussion
Although various regimens of chemotherapy have been tested in recent clinical trials involving SS patients, clinical outcomes have not improved and alternative therapies, including molecular targeting, should be eagerly explored (Antman et al., 1993; Patel et al., 1998; Frustaci et al., 2001; Edmonson et al., 2002) . SS is characterized biologically by the presence of a SYT-SSX fusion gene, which is useful for distinguishing SS from spindle-cell sarcomas that resemble it morphologically (Clark et al., 1994; van de Rijn et al., 1999) . Although the SYT-SSX fusion product may be closely involved in tumorigenesis of SS, the relevant signaling pathway remains to be clarified (dos Santos et al., 2001; Nagai et al., 2001) ; in any case, since the fusion product is a nuclear protein, an antibody-based approach to target this cancer-specific molecule is not likely to be successful. Instead, a vaccine directed against certain peptides, including fusion points, has been developed (Worley et al., 2001) . However, since peptides processed from SYT-SSX fusion protein need to be expressed on cell surfaces in association with HLA to be recognized by specific T cells, vaccination therapy will not be clinically applicable for some SS patients due to HLA restriction (Sato et al., 2002) . Therefore, from the perspective of clinical application we think an antibody targeted against a tumor-specific cell-surface molecule would carry greater therapeutic potential than a vaccine.
In this study, almost all of the SS surgical specimens and cell lines we examined showed very high levels of FZD10 transcription, whereas expression was absent or very low in the normal brain, heart, lung, liver and kidney. The relatively exclusive distribution of FZD10 expression prompted us to investigate prospects for development of a new therapeutic modality based on a specific antibody against FZD10. Among possible epitopes of FZD10-ECD detected by epitope mapping, residues 214-225 and 43-56 had similarities to FZD9 of ; novel molecuar target for synovial sarcoma therapy S Nagayama et al 72.7 and 71.4%, respectively, but we demonstrated that TT641 pAb did not react with any FZD protein other than FZD10. Therefore, monoclonal antibodies raised against these epitopes should be promising for development of molecular-targeted therapy for SS patients. Immunohistochemical analyses confirmed that endogenous FZD10 protein was almost absent in normal vital organs (brain, heart, lung and liver). This finding would underscore an advantage of antibody-based therapy, in that adverse reactions would be minimized.
The kidney, however, showed different degrees of immunoreactivity to FZD10 from one individual to another (data not shown), although no kidney signals had been detected on a Northern blot analysis (Figure 1a) . Wnt-FZD signal transduction plays a critical role in the development of the kidney (Stark et al., 1994; Kispert et al., 1998) , and we presume that a remnant of FZD protein was still reactive to TT641 pAb in the kidney tissues we examined. Alternatively, turnover of the protein may be slower in the kidney than in MTT Assays (right-hand panels) were performed 7 days after transfection; colony-formation assays were performed 13 days after transfection FZD10; novel molecuar target for synovial sarcoma therapy S Nagayama et al other tissues. From the perspective of clinical application, the finding that FZD10 may be expressed in the kidney of some individuals should be kept in mind when assessing the possibility of adverse effects. Expression of the transcript and the level of FZD10 protein were elevated in surgical specimens as well as in SS cell lines, suggesting that transduced FZD10 signals may play an important role in the pathogenesis of SS. Although the precise function of FZD10 remains to be discovered, our immunohistochemical study may provide some clues to understanding this important molecule. Epithelial tumor cells were predominantly stained in a biphasic SS specimen, and differentiated cells in the epithelia of normal colon and stomach also showed clear immunoreactivity to FZD10, suggesting the possible involvement of this protein in epithelization or polarization of cells.
In vivo experiments demonstrated attenuated growth of xenografts in nude mice after intra-tumoral injection of TT641 pAb, presumably due to induction of apoptosis, even though the antibody had no cytotoxic or growth-inhibitory effects on SS monolayers in vitro (data not shown). Furthermore, histological examination of the xenografts revealed only mild invasion of antibody-treated tumor tissues by inflammatory cells. These findings suggested that TT641 pAb alone might exert a cytotoxic effect on SS cells in vivo through stronger interactions between antigen and antibody and/ or enhanced aggregation of target molecules in the plasma membrane, mediated by antibodies. The mechanisms by which apoptotic signals were induced in the xenografts might be elucidated by in vitro analysis of three-dimensional cultures. Based on the results of our ADCC assays, we believe that cytotoxic effects would be much greater if the main effector cells were purified from peripheral blood mononuclear cells (PBMCs) and administered together with humanized antibody, although the precise involvement of PBMCs in ADCC remains to be determined. In addition, we confirmed that apoptotic cells merged positive cells with antimacrophage antibody (anti-HAM56 antibody) staining in tumor specimens of xenografts treated with TT641 pAb, suggesting that macrophage might be involved in ADCC of TT641 pAb as effector cells (data not shown).
Moreover, our analysis of expression profiles in human colon cancers metastasized to liver revealed frequent overexpression of the FZD10 gene in the metastatic lesions (data not shown). Although expression of FZD10 was almost absent in the normal adult liver, it was present in a metastatic lesion from the liver of a patient with FZD10-overexpressing colon cancer (Figure 3m and n). These findings suggest that this antibody might also be useful for detecting the presence of micrometastases in liver, and for treating FZD10-positive liver lesions via the hepatic artery with minimal adverse effects.
RNAi experiments in human SS cell lines demonstrated that the knock-down of FZD10 transcript resulted in suppression of tumor cell-growth. Furthermore, although FZD10 protein has been revealed to form homo-oligomers, there is the possibility of heterooligomerization among endogenous FZD10 and other FZD family members because several groups have reported that the Frizzled family of Wnt receptors form specific homo-and hetero-oligomers (refer Antman et al., 1993; Clark et al., 1994; Angers et al., 2000; Crist et al., 2001) . In addition, although dimerization has been documented for several GPCRs, the functional significance of that process is unclear. The betaadrenergic receptor undergoes ligand-dependent dimerization and activation, suggesting that dimerization leads to receptor/G-protein coupling (Angers et al., 2000) . The biological significance of FZD10 oligomerization needs to be investigated.
In conclusion, we successfully produced antibodies highly specific to FZD10-ECD, which were able to induce cell-mediated cytotoxic reactions in FZD10-overexpressing cells in vitro and to attenuate growth of SS xenografts in vivo. Although our data were achieved with a polyclonal preparation, we believe that anti-FZD10 antibody has great potential for development of novel drug therapies for treatment of SS and other tumors that overexpress FZD10.
Materials and methods
Cell lines, tissue specimens and transfection
Cell lines derived from SS (HS-SY-2, YaFuSS and SYO-1), colon cancers (SW480, LoVo, DLD1, HT29, HCT116, SNU- ; novel molecuar target for synovial sarcoma therapy S Nagayama et al C4 and SNU-C5), a cervical adenocarcinoma (HeLa), HEK293 and COS7 cells were grown in monolayers in appropriate media supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution, and maintained at 371C in air containing 5% CO 2 . Primary SS samples were obtained after informed consent, and either snap-frozen in liquid nitrogen immediately after resection and stored at -801C until preparation of RNA, or fixed in 10% formalin and routinely processed for paraffin embedding. The Cell-line Nucleofectort kit V (Amaxa Biosystems, Cologne, Germany) was used for transfection of SYO-1 and HS-SY-2 cells; FuGene6 (Roche) was used for other cell lines. Except for growth assays, all cells were assayed 48-72 h after transfection.
Preparation of recombinant extracellular domain (rECD) of FZD10
FZD10 rECD (residues 1-225) DNA fragment was generated by PCR amplification with the following primers; 5 0 -AAA GAATTCATGCAGCGCCCGGGC-3 0 and 5 0 -AAAAAGC TTTCAGCGCTTGTCCTCGCGGCT-3 0 . The PCR products were digested with EcoRI and HindIII, and ligated into pET28a( þ ) (Novagen). Recombinant His-tagged protein was expressed in Escherichia coli strain BL21 codonplus (DE3) (Stratagene). After induction with 0.5 mM isopropyl-b-Dthiogalactopyranoside (IPTG), the bacteria pellet was suspended with lysis buffer under denaturing conditions, 100 mM sodium phosphate, 10 mM Tris, 6 M guanidine-HCl and 10 mM imidazole, pH 8.0, and were purified with Ni-NTA superflow (Qiagen) following the manufacturer's instructions. The protein was eluted with 100mM sodium phosphate, 10 mM Tris, 8 M urea and 300 mM imidazole, pH 8.0. The eluted protein was dialysed against 100 mM sodium phosphate, 10 mM Tris, 8 M urea and 20 mM imidazole, pH 8.0, and further purified with TALONt Superflowt Metal Affinity Resin (BD Clontech) following the manufacturer's instructions. The denatured protein was refolded by gradual removal of urea by means of stepwise dialysis from 8 to 0.5 M.
Polyclonal antibody against FZD10
Polyclonal anti-FZD10 antibodies (TT641 pAb) were raised in rabbits against a purified FZD10-rECD (residues 1-225) recombinant protein (Medical and Biological Laboratories, Nagoya, Japan). The high-titer antiserum was affinity-purified using the FZD10-rECD-coupled support (Affigel 15; BioRad, Hercules, CA, USA).
Epitope mapping
A series of 10-residue linear synthetic peptides overlapping by one amino acid and covering the entire FZD10-ECD were covalently bound to a cellulose membrane (SPOTs; Sigma Genosys, Woodlands, TX, USA). The membrane, containing 216 peptide spots, was hybridized with TT641 pAb overnight at 41C. After incubation with anti-rabbit HRP-conjugated IgG (Amersham Bioscience, Piscataway, NJ, USA), the spots were visualized with 3-amino-9-ethylcarbazole.
Construction of siRNA expression vector, psiU6X3.0
The snRNA U6 gene is transcribed by RNA polymerase III to produce short transcripts with uridines at the 3 0 end. We amplified by PCR a genomic fragment containing the promoter region of snRNA U6, using human placental DNA as a template and primers 5 0 -GGGGATCAGCGTTTGAG TAA-3 0 and 5 0 -TAGGCCCCACCTCCTTCTAT-3 0 . The product was purified and cloned into pCR plasmid vector using a TA cloning kit, according to the supplier's protocol (Invitrogen). A BamHI, XhoI-digested fragment containing the snRNA U6 gene was purified and cloned into pcDNA3.1( þ ) between nucleotides 1257 and 1256; then amplified by PCR using primers 5 0 -TGCGGATCCAGAGCAGATTGTACTGAGA GT-3 0 and 5 0 -CTCTATCTCGAGTGAGGCGGAAAGAA CCA-3 0 . This ligated DNA was used as the template for PCR with primers 5 0 -TTTAAGCTTGAAGACTATTTTTACATC AGGTTGTTT TTCT-3 0 and 5 0 -TTTAAGCTTGAAGACA CGGTGTTTCGTCCTTTCCACA-3 0 (underline indicates the Hind III site). After digestion with HindIII, the product selfligated to produce a vector plasmid, psiU6BX3.0.
Plasmid construction
To generate the HA-FLAG tag, a following set of oligonucleotides, 5 0 -ACGTGTCGACTACCCATACGACGTCCCA GACTACGCTATGGACTACAAGGACGACGATGACAA GCTCGAGATGC-3 0 (underline indicates SalI site) and 5 0 -GCATCTCGAGCTTGTCATCGTCGTCCTTGTAGTCCA TAGCGTAGTCTGGGACGTCGTATGGGTAGTCGTAT GGGTAGTCGACACGT-3 0 (underline indicates the XhoI site) was annealed and digested with SalI and XhoI. Fragments containing residues 1-217 and 218-stop codon (or C-terminal deletion) were individually amplified by PCR; after digestion with SalI and XhoI, the products were ligated sequentially into pCAGGS/neo expression vector. An HA-FLAG tag, also digested with SalI and XhoI, was ligated in-frame between nucleotides 651 and 652.
Plasmids expressing siRNAs specific to FZD10 were prepared by cloning the double-stranded oligonucleotides into psiU6BX3.0 vector (Table 1) . Complementary oligonucleotides were each phosphorylated by incubation with T4-polynucleotide kinase at 37 o C for 30 min, followed by boiling and then slow cooling to room temperature to anneal the two oligonucleotides. Each product was ligated into psiU6BX3.0 to construct an FZD10-siRNA expression vectors. The genesilencing effect of each vector was verified by semiquantitative RT-PCR.
Semiquantitative RT-PCR and Northern blot analysis
For RT-PCR experiments, total RNAs were extracted from cell lines and from frozen surgical specimens using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and a 3-mg aliquot of each total RNA was reverse-transcribed. PCR amplification was performed using the cDNAs as templates and the following primers: 5 0 -TATCGGGCTCTTCTCTGTGC-3 0 and 5 0 -GACTGGGCAGGGATCTCATA-3 0 for FZD10; 5 0 -CTGCACGCTGGTCTTCCTCT-3 0 and 5 0 -CCGATCTTG ACCATGAGCTTC-3 0 for FZD9; and 5 0 -TTAGCTGTGCT CGCGCTACT-3 0 and 5 0 -TCACATGGTTCACACGGCAG-3 0 for b2-microglobulin (b2MG), the internal control. For Northern blot analysis, a 1-mg aliquot of each mRNA isolated using Micro-FastTrack (Invitrogen), and human normal-tissue polyA( þ ) RNAs (Clontech, Palo Alto, CA, USA), was separated on a 1% denaturing agarose gel, transferred to a nylon membrane, and probed using a 32 P-dCTP-labeled FZD10 cDNA.
Cell-growth assays
SYO-1 and HS-SY-2 cells transfected with psiU6 plasmids were maintained in media containing appropriate concentrations of geneticin. Cell viability was measured by MTT assay 7 days later, using cell-counting kit8 (Dojindo). For FZD10; novel molecuar target for synovial sarcoma therapy S Nagayama et al colony-formation assays, 13 days (SYO-1) or 8 days (HS-SY-2) after geneticin selection the cells were fixed with 4% paraformaldehyde and stained with giemsa solution.
Immunoprecipitation
Transfected COS-7 cells were washed twice with cold PBS(À) and lysed in IPP buffer (10 mM Tris-HCl pH8.0, 150 mM NaCl, 0.1% NP-40, 1 mM NaF and appropriate protease inhibitors). The cell lysates were incubated with anti-HA F7 antibody (Santa Cruz) and protein G-sepharose (Sigma). Bound proteins were washed five times with IPP buffer and eluted with SDS-sample buffer. Eluted proteins were analysed by SDS-PAGE and Western blotting.
Western blotting
Cell lysates and immunoprecipitates were separated on 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes, followed by incubation with TT641 pAb, antimyc 9E10 monoclonal antibody, or anti-HA F7 antibody. Following incubation with mouse anti-c-myc antibody (9E10) and with the TT641 pAb (2 mg/ml), primary antibodies were double-stained with anti-mouse (Texas Red) and anti-rabbit (Alexa Fluor 488) fluorescent antibodies, stained with DAPI, and visualized with an ECLIPSE E600 microscope (Nikon, Tokyo, Japan). SS cell lines were immunostained with TT641 pAb in the same manner to detect endogenous expression of FZD10.
Flow cytometry
Suspensions of 5 Â 10 6 cells were incubated with 1.5 mg of TT641 pAb or nonimmunized rabbit IgG (DAKO, Kyoto, Japan) for 30 min at 4 o C. After washing with PBS, 2 mg of fluorescent anti-rabbit IgG (Alexa Fluor 488, Molecular Probes, Eugene, OR, USA) was added, and the cell suspension was incubated for 30 min at 41C for analysis by FACScan (Becton Dickinson, San Jose, CA, USA).
Immunohistochemical staining
Slides of paraffin-embedded normal adult human tissues (BioChain, Hayward, CA, USA) and surgical SS specimens were processed for antigen retrieval by microwave treatment, and incubated with 5 mg/ml TT641 pAb. Subsequently, rabbit ENVISION Polymer Reagent (DAKO) was added and visualized with peroxidase substrate (3, 3 0 -diaminobenzidine tetrahydrochloride).
ADCC assay
Cytotoxicity was assayed by quantitative measurement of LDH, using the CytoTox96 Nonradioactive Cytotoxicity Assay (Promega, Madison, WI, USA). Fresh effector cells were isolated from heparinized peripheral blood of a healthy donor by Ficoll-Plaque (Amersham Bioscience). Effector cells (E) and target cells (T) (each, 5 Â 10 3 /well) were coincubated for 6 h at 371C in quadruplicate at various E : T ratios, together with TT641 pAb or nonimmunized rabbit IgG, in 100 ml of phenol red-free RPMI 1640 supplemented with 5% FBS in a 96-well-plate. LDH released in the culture supernatants was determined by absorbance at 490 nm. The percentage of specific cytotoxicity was calculated according to the manufacturer's instructions. Controls included target and effector cells incubated separately with TT641 pAb.
Treatment of SS xenografts with antibody
In vivo experiments were performed in our animal facility in accordance with institutional guidelines. A 0.1-ml aliquot of suspended SYO-1 cells (5 Â 10 6 cells) was injected subcutaneously into the flanks of 6-week-old female athymic mice (BALB/cA Jcl-nu). Tumor volumes were determined using the formula: 0.5 Â (larger diameter) Â (smaller diameter) 2 . When the xenografts were 40-75 mm 3 in size, animals were randomly divided into two groups. One group (n ¼ 16) received intratumoral injection of 10 mg of TT641 pAb for 5 consecutive days. The other group (n ¼ 15) received nonimmunized rabbit IgG (DAKO) as a control. Tumor growth was assessed by calculating the ratio of tumor volume on the indicated day to the volume calculated on the initiation of treatment. The tumors were removed at designated times, and paraffinembedded slides were stained for TUNEL assays using the ApopTag Apoptosis Detection Kit (Intergen). The proliferative ability of the cells was assessed by immunohistochemical staining with anti-Ki-67 mouse monoclonal antibody (MIB-1, DAKO).
Abbreviations SS, synovial sarcoma; FZD10, frizzled homologue 10; siRNA, small-interfering RNA; ADCC, antibody-dependent cellmediated cytotoxicity; ECD, extracellular domain.
